La migraña afecta a mucha gente en el mundo. Se estima que en países como España la sufre el 12% de la población. Incluso con los avances de los últimos años, hay personas que, a pesar de haber probado todos los tratamientos preventivos disponibles, …
Nueva opción para los casos de migraña más difíciles de tratar Read More »
Molina’s second quarter was complicated, with stability in Medicaid and outperformance in Medicare Advantage overshadowed by problems in the ACA exchanges. The trend was “unfortunate,” according to the insurer’s CEO.
The addition of small molecule capacity at BeOne Medicines’ Hopewell site will support the company’s hematology efforts and bring total investment in the campus to more than $1 billion.
BeOne commits $300M to US manufacturing expansion, creating 120 new jobs Read More »
Brian Manning, who previously worked at health tech companies like Bamboo Health and Zocdoc, replaces the AI company’s co-founder and former CEO Alex LeBrun.
With weight loss topping 20% at 80 weeks in the Phase 3 TRIUMPH-2 and TRIUMPH-3 trials, Eli Lilly plans to file for retatrutide’s approval in the first quarter of 2027. Earlier data from TRIUMPH-1 showed weight loss reaching a record-breaking 28.3%.
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data Read More »
Jideytro is GSK’s first approved product for lung cancer. With its takeover of Nuvalent Bio last month and a deal with Hansoh Pharmaceutical in 2023, the pharma now has several other lung cancer assets in late-stage development.
GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug Read More »
Roche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker said on the pharma’s Q2 earnings call.
Roche’s late stage pipeline “so full” CEO Schinecker not feeling pressure to add on Read More »
In this episode of Denatured, you’ll hear from Ester Sklarsky, principal at Sound Bioventures and João Ribas, partner at Novo Holdings Seed Investments. In this episode, we explore the diverging trajectories of Nordic biotech and what it will take for the region, including Norway and Finland, to compete more cohesively on the global stage. .
Nordic biotech’s next act: From fragmentation to global force Read More »
Las paredes de la Cámara de Síntesis no eran de metal ni de piedra, sino de una geometría fractal de luz sólida que vibraba a frecuencias apenas audibles. En el centro, flotando en un vacío magnético, se agitaba una neblina de nanobots, una sopa primordial d …
Arqueología del Código Muerto (Víctor Arenas) (Relato de CF) Read More »
La historia de nuestra civilización suele contarse a través de grandes batallas, reyes y fronteras trazadas en mapas. Sin embargo, la verdadera transformación de la humanidad no la firmaron los generales, sino los artesanos que, hace más de tres milenios, aprendieron a do …
Grandes inventos de la humanidad: La metalurgia del hierro Read More »
